MedTrace Logo

Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2

NCT06316843 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2025-01-22

No results posted yet for this study

Summary

To explore the safety and efficacy of daily doses of celecoxib + valacyclovir in the treatment of patients with prolonged symptoms caused by COVID-19.

Conditions

Interventions

DRUG

Valacyclovir celecoxib dose 1

1500 mg valacyclovir 200 mg celecoxib taken two times a day

DRUG

Valacyclovir celecoxib dose 2

750 mg valacyclovir 200 celecoxib mg taken two times a day

DRUG

Placebo

Placebo capsules colored matched to investigational product taken two times a day

Sponsors & Collaborators

  • Bateman Horne Center

    lead OTHER

Principal Investigators

  • Lucinda Bateman, MD · Bateman Horne Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-15
Primary Completion
2024-10-31
Completion
2024-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06316843 on ClinicalTrials.gov